Vancouver, British Colombia – (NewsFile Corp. – January 31, 2025) – Moss Genomics Inc. It was previously announced from the previously announced arrow of 2,500,000 joint shares (each arrow “) at $ 0.10 per share for the total total returns of $ 250,000 (” offer “). Meanwhile, with the closing of the offer, the company announces the closure of its acquisition of 160 ETHEREUM CRYPTOCURNCY (“” ETH “) in mind for version 7,840,000 joint shares (” ETH “).
The offer and ERTH are still subject to the final acceptance of the Canadian stock exchange. All securities issued in terms of offers and ERTH will be subject to a legal suspension period that ends for four months in addition to one day of closure.
The company intends to use clear revenues for offer and gain Ert for the public capital purposes.
The securities that are submitted and will not be registered under the US Securities Law and they may not be presented or sold in the United States, or for an account or useful of persons or persons in the United States. Registration or exemption in force from registration requirements. This press statement will not constitute an offer for sale or petition offered to buy or there must be any sales of securities in any case in which this offer, contact or illegal sale.
Hunter is appointed Jordan
The company is pleased to announce that it has appointed Hunter Jordan on its board of directors.
Hunter is a vice president of a private real estate company, specializing in the investments of the Global Real Estate Company. In this role, it leads strategic initiatives to create and expand platforms while improving governance structures. Hunter started his career in PWC, obtained his CPA appointment, and worked in many sectors and regions.
The company also announces that it has given a total of 200,000 shares options for some managers, officials and advisers to the company. Each option can be practiced to buy one shared share of the company at an exercise price of $ 0.20 for 5 years.
About Moss Genomics Inc.
Moss is a biotechnology company that uses artificial intelligence, genome, microbium, and a variety of health data to develop unique and innovative health solutions. By merging Blockchain and advanced treasury strategies, Moss seeks to take advantage of modern technology developments in the life science industry.
For more information related to MOSS and its work, please display the company’s website on the company’s website MossGenomics.com And sedar+ profile in www.sedarplus.ca Or contact us on:
Contact information Moss Genomics Inc. Jack Liu, CEO and director Email: Invest@mossen.co Phone: 604-710-0124
The contents of this press statement were not approved, not clarified or rejected. Neither the CSE nor the market organizer (as defined in CSE) are responsible for the adequacy or accuracy of this version.
Information looking forward
This version includes some data and information that may constitute aspecting information in the meaning intended in the applicable Canadian Securities Laws. The aspiration data is related to future events or future performance and reflects the expectations or beliefs of the company’s management regarding future events. In general, the data and aspiration information can be identified through the use of aspecting terms such as “repeat” or “expectation”, or differences in these words, phrases or phrases that may be some procedures, events or results “,”, “,”, “,,, “,” It is possible “,” must “,” will “or” speak “. This information and data, which are referred to here in the name of” front appearance data “, are not historical facts, and it is issued as of the date of this news version and includes this without restrictions, data Concerning the discussions of plans, estimates and future data, as well as the expectations and intentions of the administration in relation to, among other matters: organizational approval of the offer, the acquisition of ETH and the intended use of the revenues that were raised according to the offer.
These future phrases include many risks and doubts, and actual results may differ financially from the proposed results in any aspective data. These risks and doubts include, among other things: delay in obtaining or failing to obtain the regulatory approvals required for offer and gain ETH; Uncertainty in the market. The changes in the company’s business plans that affect the intended use of the returns raised under the offer.
When giving up the looking forward data in this news statement, the company has applied many material assumptions, including but not limited to, that the company will obtain the regulatory approvals required for offers and ETH acquisition; The company will use the offer revenues as expected.
Although the management of the company has attempted to determine the important factors that can cause actual results materially from those mentioned in the aspiration or aspiration information, there may be other factors that cause not expected, estimated or intended results. There can be no guarantee that such data will prove that they are accurate, as actual results and future events can differ materially from those expected in such phrases. Accordingly, readers should not rely on aspecting data and aspiration information. Readers are warned that relying on this information may not be suitable for other purposes. The company does not undertake to update any aspecting statement, aspecting information, or the financial view that is integrated with reference here, with the exception of the applicable securities laws.
